Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.
RJ, C., C, P., HL, D., C, T., A, L., C, D.T., A, F.M., SS, H., N, L., & K, B. (2026). Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71588
RJ C, C P, HL D, C T, A L, C DT, et al. Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026; doi: 10.1002/alz.71588
RJ C, C P, HL D, et al. Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.[J]. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. DOI: 10.1002/alz.71588.
@article{rj2026,
author = {Cottez RJ and Peyrot C and Denis HL and Tremblay C and Loiselle A and Dallaire-Théroux C and Filali-Mouhim A and Hébert SS and Leclerc N and Blennow K},
title = {Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71588},
note = {PMID: 42273887},
}
TY - JOUR AU - Cottez RJ AU - Peyrot C AU - Denis HL AU - Tremblay C AU - Loiselle A AU - Dallaire-Théroux C AU - Filali-Mouhim A AU - Hébert SS AU - Leclerc N AU - Blennow K TI - Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort. T2 - Alzheimer's & dementia : the journal of the Alzheimer's Association PY - 2026 DO - 10.1002/alz.71588 AN - PMID:42273887 ER -
INTRODUCTION: We evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease-Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p < 0.001). Hypertension was further linked to steeper memory and executive function decline (β = -0.10, both p = 0.04) in this group, and it amplified the effect of p-tau217 on cognitive decline across the whole group. Higher p-tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p-tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.